Researchers have solved the first step in treating the common cold, by mapping its entire genome, or genetic map, teams from the University of Maryland and the University of Wisconsin-Madison reported ...

Between September 2003 and July 2005, we studied a total of 382 children <2 years of age admitted to hospital with respiratory tract infection. We obtained NPA samples and clinical data for 340 cases ...

The family of viruses responsible for the common cold was linked to a lower risk of SARS-CoV-2 infection, according to a prospective analysis of the Human Epidemiology and Response to SARS-CoV-2 ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 AMSTERDAM, Sept. 28, 2025 ...

Rhinoviruses and endemic coronaviruses are the main causes of the common cold. Recent studies show “common” cold viruses can cause severe and even fatal illness in healthy adults. Infection with ...

VirTus Respiratory Research Ltd, a leading respiratory-focused contract research organisation (CRO), today announced that results from their human rhinovirus challenge model in patients with chronic ...

No one wants to catch the common cold, but it’s certainly better than a COVID-19 infection for more reasons than one. With a cold, there’s no chance of developing long COVID, much less of a likelihood ...

Hospitals across China are reporting a significant increase in respiratory cases among children, coinciding with the ...

China is currently experiencing an increase in influenza, respiratory syncytial virus, rhinovirus, and other acute ...

You've been through winter lurgies and escaped the start of spring free of hay fever. Now you wake up with a sniffle you ...

An everyday hay fever spray may do more than tame sneezes. In a rigorously run German trial, adults who used azelastine nasal spray three times a day were less likely to catch COVID-19 than those who ...

Treatment improved patient reported outcomes, reduced viral load, and maintained lung function compared to placebo; Multi-center, international trial slated for 2026 Dr. Brett Giroir, Chief Executive ...